Los resultados del ensayo RALES constituyen una buena noticia para los pacientes con insuficiencia cardíaca y... Las administraciones sanitarias

Medicina Clinica

Volumn 114, Issue 14, 2000, Pages 545-550

  Azpitarte Almagro, José ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; RAMIPRIL; SPIRONOLACTONE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

EID: 0034655994     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(00)71358-3     Document Type: Article

References (45)

1. Rodriguez-Artalejo F, Guallar-Castillón P, Banegas Banegas JR, Del Rey Calero J. Trends in hospitalization and mortality for heart failure in Spain, 1980-1993. Eur Heart J 1997; 18: 1771-1779.
2. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC et al. The epidemiology of heart failure. Eur Heart J 1997; 18: 208-225.
3. Goldberg JR, Konstam MA. Assessing the population burden from heart failure: need for sentinel population-based surveillance systems. Arch Intern Med 1999; 159: 15-17.
4. Hoes AW, Mosterd A, Grobbee DE. An epidemic of heart failure? Recent evidence from Europe. Eur Heart J 1998; 19 (Supl L): 2-9.
5. Ryden-Bergsten T, Andersson F. The health care costs of heart failure in Sweden. J Intern Med 1999; 246: 275-284.
6. Antoñanzas Villar F, Antón Botella F, Juárez Castelló CA, Echevarría Echarri L. Costes de la insuficiencia cardiaca crónica en España. An Med Intema 1997; 14: 9-14.
7. MacKowiac J. Cost of the heart failure to the healthcare system. Am J Manag Care 1998; 6: S338-S342.
8. Krumholz HM, Parent EM, Tu N, Vaccarino V, Wang Y, Radford MJ et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997; 157: 99-104.
9. Zannad F, Braincon S, Juilliere Y, Mertes PM, Villemot JP, Alla F et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidemiologie de l'Insuffisance Cardiaque Avancée en Lorraine. J Am Coll Cardiol 1999; 33: 734-742.
10. McDermott MM, Feinglass J, Lee P, Mehta S, Schmitt B, Lefevre F et al. Heart failure between 1986 and 1994: temporal trends in drug-prescribing practices, hospital readmissions, and survival at an academic medical center. Am Heart J 1997; 134: 901-909.
11. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 10; 273: 1450-1456.
12. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Pérez A et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patents with severe heart failure. N Engl J Med 1999; 341: 709-717.
13. Smith AGE. Spironolactone in the long-term management of patients with congestive heart failure. Curr Med Res Opin 1980; 7: 131-136.
14. Van Vliet AA, Donker AJM, Nauta JJP, Verheugt FWA. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensing-converting enzyme inhibitor. Am J Cardiol 1993; 71: 21A-28A.
15. Brilla CG, Pick R, Tan LB, Janicli JS, Weber KT. Remodelling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67: 1355-1364.
16. Weber KT, Brilla CG. Pathologica hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
17. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Moll Cell Cardiol 1993; 25: 563-575.
18. Brilla CG, Zhou G, Matsubara LS, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Moll Cell Cardiol 1994; 26: 809-820.
19. Funk RC, Wilke A, Rupp H, Brilla CG. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol 1997; 432: 35-44.
20. Lombès M, Oblin M-E, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992; 71: 503-510.
21. Lombès M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11β-Hydroxysteroid dehydrogenase in the human heart. Circulation 1995; 92: 175-182.
22. Schofer J, Spielma R, Schuchert A, Weber K, Schlüter M. Iodine-123 metaiodobenzylguanidine scintigraphy: a non-invasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988; 12: 1252-1258.
23. Merlet P, Valette H, Dubois Rande J-L, Moise D, Duboc D, Dove P et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33: 471-477.
24. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary heart disease. Am J Cardiol 1995; 76: 1259-1265.
25. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997; 35: 30-34.
26. Panina G, Nunziate E, Cody RJ, Binldey PF. Low frequency heart rate variability as a marker of disease progression in congestive heart failure. Circulation 1995; 92: 3475.
27. Kleiger RE, Miller P, Bigger JT, Moss AJ. Decrease heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256-262.
28. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994; 24: 571-575.
29. Hatakeyama H, Miyamori I, Futjita T, Takeda I, Takeda R, Yamamoto H. Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994; 269: 24316-24320.
30. Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19: 1371-1376.
31. Tait JF, Bougas J, Little B, Tait SAS, Flood C. Splanchnic extraction and clearance of aldosterone in subjects with minimal and marked cardiac dysfunction.
32. Nicholls MG, Espiner EA, Ronald RA, Hughes H. Aldosterone and its regulation during diuresis in patients with gross congestive heart failure. Clin Sci Mol Med 1974; 47: 301-315.
33. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91: 457-465.
34. Borghi C, Boschi S, Ambosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993; 33: 40-45.
35. Zannad F. Aldosterone and heart failure. Eur Heart J 1995; 16 (Supl N): 98-102.
36. Pitt B. «Escape» of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995; 9: 145-149.
37. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: the RESOLVD pilot study investigators. Circulation 1999; 100: 1056-1064.
38. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS trial study group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-1736.
39. The RALES Investigators. Effectiveness of spironolactone added to an angiotensinconverting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78: 902-907.
40. CIBIS-II Investigators and Committees. The cardiac insufficiency oisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
41. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
42. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327: 685-691.
43. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
44. Erhardt L, Ball S, Anderson F, Bergentoft P, Martínez C. Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy. Pharmacoeconomics 1997; 12: 256-266.
45. Schadlich PK, Huppertz E, Brecht JG. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance. Pharmacoeconomics 1998; 14: 653-669.